Don't Jump to an SGLT2 Inhibitor for Heart Failure

You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart patients withOUT diabetes.

Prior evidence suggests that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).

New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote